---
title: Papers
author: Synnøve Yndestad
date: '2024-01-13'
slug: []
categories: []
tags: []
excerpt: '1.	**Yndestad, S**., C. Engebrethsen, A. Herencia-Ropero, O. Nikolaienko, O. K. Vintermyr, R. K. Lillestol, L. Minsaas, B. Leirvaag, G. T. Iversen, B. Gilje, E. S. Blix, H. Espelid, S. Lundgren, J. Geisler, H. S. Aase, T. Aas, E. G. Gudlaugsson, A. Llop-Guevara, V. Serra, E. A. M. Janssen, P. E. Lonning, S. Knappskog and H. P. Eikesdal (2023). [**Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer**](https://pubmed.ncbi.nlm.nih.gov/38039432/) 
JCO Precis Oncol 7: e2300338.  


2.	Nikolaienko, O., H. P. Eikesdal, E. Ognedal, B. Gilje, S. Lundgren, E. S. Blix, H. Espelid, J. Geisler, S. Geisler, E. A. M. Janssen, **S. Yndestad**, L. Minsaas, B. Leirvaag, R. Lillestol, S. Knappskog and P. E. Lonning (2023). [**Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development**](https://pubmed.ncbi.nlm.nih.gov/38053165/) Genome Med 15(1): 104.  


3.	Eikesdal, H. P., **S. Yndestad**, A. Elzawahry, A. Llop-Guevara, B. Gilje, E. S. Blix, H. Espelid, S. Lundgren, J. Geisler, G. Vagstad, A. Venizelos, L. Minsaas, B. Leirvaag, E. G. Gudlaugsson, O. K. Vintermyr, H. S. Aase, T. Aas, J. Balmana, V. Serra, E. A. M. Janssen, S. Knappskog and P. E. Lonning (2021). [**Olaparib monotherapy as primary treatment in unselected triple negative breast cancer**](https://pubmed.ncbi.nlm.nih.gov/33242536/) Ann Oncol 32(2): 240-249.  


4.	**Yndestad, S.**, E. Austreid, K. O. Skaftnesmo, P. E. Lonning and H. P. Eikesdal (2018). [**Divergent Activity of the Pseudogene PTENP1 in ER-Positive and Negative Breast Cancer**](https://pubmed.ncbi.nlm.nih.gov/29021233/) Mol Cancer Res 16(1): 78-89.  


5.	**Yndestad, S.**, E. Austreid, I. R. Svanberg, S. Knappskog, P. E. Lonning and H. P. Eikesdal (2017). [**Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines**](https://pubmed.ncbi.nlm.nih.gov/28476032/) Oncotarget.  


6.	**Yndestad, S.**, E. Austreid, S. Knappskog, R. Chrisanthar, P. K. Lilleng, P. E. Lonning and H. P. Eikesdal (2017). [**High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function**](https://pubmed.ncbi.nlm.nih.gov/28213783/) Breast Cancer Res Treat.  


7.	Steinskog, E. S., S. J. Sagstad, M. Wagner, T. V. Karlsen, N. Yang, C. E. Markhus, **S. Yndestad**, H. Wiig and H. P. Eikesdal (2016). [**Impaired lymphatic function accelerates cancer growth**](https://pubmed.ncbi.nlm.nih.gov/27329584/) Oncotarget.  


8.	Knappskog, S., E. O. Berge, R. Chrisanthar, S. Geisler, V. Staalesen, B. Leirvaag, **S. Yndestad, E**. de Faveri, B. O. Karlsen, D. C. Wedge, L. A. Akslen, P. K. Lilleng, E. Lokkevik, S. Lundgren, B. Ostenstad, T. Risberg, I. Mjaaland, T. Aas and P. E. Lonning (2015). [**Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo**](https://pubmed.ncbi.nlm.nih.gov/26004085/) Mol Oncol.  


9.	**Yndestad S**, Eikesdal HP, [**PI3K-Akt-mTOR signallering og Anthracyclinresistens**](https://onkonytt.no/pi3k-akt-mtor-signalering-og-anthracyklinresistens/). Onkonytt. 2014(1).

  
<br>    
      
      
#### Scientific meeting posters  
  
    
1.	**Synnøve Yndestad.** “Digital PD-L1 CPS score: A workflow for Positive cell detection and classification using QuPath.” Bringing AI and Precision Medicine to Patient Care, The Sixth Annual MMIV Conference Bergen (2023).   


2.	PS07-09 Prenatal BRCA1 epimutations is a major cause of triple-negative breast cancer. Per Lonning, Hans Petter Eikesdal, Elisabet Ognedal, Bjornar Gilje, Steinar Lundgren, Egil Blix, Helge Espelid, Jürgen Geisler, Stephanie Geisler, Emiel Janssen, **Synnøve Yndestad**, Laura Minsaas, Beryl Leirvaag, Reidun Lillestol, Stian Knappskog, Oleksii Nikolaienko. SABC (2023).   


3.	**S. Yndestad**, Engebrethsen, C., A. Herencia-Ropero, O. Nikolaienko, O. K. Vintermyr, R. K. Lillestøl, L. Minsaas, B. Leirvaag, G. Iversen, B. Gilje, E. Blix, H. Espelid, S. Lundgren, J. Geisler, L. J. Vassbotn, H. S. Aase, T. Aas, A. Llop-Guevara, V. Serra, P. E. Lønning, S. Knappskog and H. P. Eikesdal. "Abstract P6-10-04: Homologous recombination deficiency across subtypes of primary breast cancer." Cancer Research 83(5_Supplement): P6-10-04-P16-10-04. (2023)  


4.	Eikesdal, H. P., **Yndestad, S.**, Blix, E. S., Lundgren, S., Vagstad, G., Espelid, H., Gilje, B., Janssen, E. A., Geisler, J., Aas, T., Aase, H., Knappskog, S., Lønning, P. E.Neoadjuvant olaparib monotherapy in primary triple negative breast cancer. Annals of Oncology 2019; 30.  


5.	**Synnøve Yndestad**, Eilin Austreid, Ida R. Svanberg, Per E. Lønning, Hans P. Eikesdal. "The Role of Akt in Anthracyclin Resistance in Patients with Locally Advanced Breast Cancer." 4rth CCBIO symposium, Solstrand (2016).  


6.	**Synnøve Yndestad**, Eilin Austreid, Kai Ove Skaftnesmo, Per Eystein Lønning, Hans Petter Eikesdal. "Introduction of Pten Pseudogene in Murine Breast Cancer Upregulates Pten, P53 and Activating Protein 2 Gamma and Delays Tumor Growth.". AACR 106th Annual Meeting 2015; Apr 18–22, 2015; Philadelphia, PA, no. Poster Presentation, Abstract number 3986 (2015).  


7.	**Yndestad Synnøve**, Austreid Eilin, Eikesdal Hans Petter. "The Non-Coding Pten Pseudogene Influences Pi3k Signaling and Inhibits Breast Cancer Progression." AACR 105th Annual Meeting 2014; Apr 5–9, 2014; San Diego, CA, no. Poster presentation, Abstract number 3539 (2014).
8.	Austreid, E. Yndestad, S.  Knappskog, S. Lønning, P.E. Eikesdal, H.P. "The Influence of Doxorubicin on Pten and Pi3k-Akt-Mtor Signaling in Human Breast Cancer." San Antonio Breast Cancer Symposium Poster Presentation  (2013).  


9.	Eikesdal Hans Petter, Austreid Eilin, **Yndestad Synnøve**, Knappskog Stian, Lonning Per Eystein. "Pten Pseudogene Downregulates Pten in Human Breast Cancer." Keystone Poster presentation  (2012).  


10. **Yndestad Synnøve**, Roiha Irja Sunde, Torsvik Vigdis, Brandvik Per Johan, Øvreås, Lise.
Microbial community analysis of a hydrocarbon-contaminated arctic soil from Svalbard. 1st Workshop on Microbial ecology and bioremediation in cold climate (MECBIO). Bergen (2002) UiB UNIS  


11. **Yndestad Synnøve**, Roiha Irja Sunde, Torsvik Vigdis, Brandvik Per Johan, Øvreås Lise.
Microbial community analysis of a hydrocarbon-contaminated arctic soil from Svalbard. 7th Symposium on Bacterial Genetics and Ecology (BAGECO-7) (2002) UiB UNIS. 


12. **Yndestad Synnøve**, Roiha Irja Sunde, Øvreås Lise, Brandvik Per Johan.
Oil pollution in the Arctic and its effect on microbial diversity and ecology. Mikrobiologisk vintermøte (2002) UiB UNIS


### PhD thesis 

**The role of PTEN, PI3K-Akt-mTOR signaling and pseudogene PTENP1 in breast cancer**
2018 University of Bergen

[Lint to thesis](https://bora.uib.no/bora-xmlui/handle/1956/17687)


### Master/Cand. Scient thesis  

**Mikrobiell diversitet i oljeforurenset og uberørt tundra på Svalbard**

https://bora.uib.no/bora-xmlui/handle/1956/17687


'
---


1.	**Yndestad, S**., C. Engebrethsen, A. Herencia-Ropero, O. Nikolaienko, O. K. Vintermyr, R. K. Lillestol, L. Minsaas, B. Leirvaag, G. T. Iversen, B. Gilje, E. S. Blix, H. Espelid, S. Lundgren, J. Geisler, H. S. Aase, T. Aas, E. G. Gudlaugsson, A. Llop-Guevara, V. Serra, E. A. M. Janssen, P. E. Lonning, S. Knappskog and H. P. Eikesdal (2023). [**Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer**](https://pubmed.ncbi.nlm.nih.gov/38039432/) 
JCO Precis Oncol 7: e2300338.  

2.	Nikolaienko, O., H. P. Eikesdal, E. Ognedal, B. Gilje, S. Lundgren, E. S. Blix, H. Espelid, J. Geisler, S. Geisler, E. A. M. Janssen, **S. Yndestad**, L. Minsaas, B. Leirvaag, R. Lillestol, S. Knappskog and P. E. Lonning (2023). [**Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development**](https://pubmed.ncbi.nlm.nih.gov/38053165/) Genome Med 15(1): 104.  

3.	Eikesdal, H. P., **S. Yndestad**, A. Elzawahry, A. Llop-Guevara, B. Gilje, E. S. Blix, H. Espelid, S. Lundgren, J. Geisler, G. Vagstad, A. Venizelos, L. Minsaas, B. Leirvaag, E. G. Gudlaugsson, O. K. Vintermyr, H. S. Aase, T. Aas, J. Balmana, V. Serra, E. A. M. Janssen, S. Knappskog and P. E. Lonning (2021). [**Olaparib monotherapy as primary treatment in unselected triple negative breast cancer**](https://pubmed.ncbi.nlm.nih.gov/33242536/) Ann Oncol 32(2): 240-249.  

4.	**Yndestad, S.**, E. Austreid, K. O. Skaftnesmo, P. E. Lonning and H. P. Eikesdal (2018). [**Divergent Activity of the Pseudogene PTENP1 in ER-Positive and Negative Breast Cancer**](https://pubmed.ncbi.nlm.nih.gov/29021233/) Mol Cancer Res 16(1): 78-89.  

5.	**Yndestad, S.**, E. Austreid, I. R. Svanberg, S. Knappskog, P. E. Lonning and H. P. Eikesdal (2017). [**Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines**](https://pubmed.ncbi.nlm.nih.gov/28476032/) Oncotarget.  

6.	**Yndestad, S.**, E. Austreid, S. Knappskog, R. Chrisanthar, P. K. Lilleng, P. E. Lonning and H. P. Eikesdal (2017). [**High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function**](https://pubmed.ncbi.nlm.nih.gov/28213783/) Breast Cancer Res Treat.  

7.	Steinskog, E. S., S. J. Sagstad, M. Wagner, T. V. Karlsen, N. Yang, C. E. Markhus, **S. Yndestad**, H. Wiig and H. P. Eikesdal (2016). [**Impaired lymphatic function accelerates cancer growth**](https://pubmed.ncbi.nlm.nih.gov/27329584/) Oncotarget.  

8.	Knappskog, S., E. O. Berge, R. Chrisanthar, S. Geisler, V. Staalesen, B. Leirvaag, **S. Yndestad, E**. de Faveri, B. O. Karlsen, D. C. Wedge, L. A. Akslen, P. K. Lilleng, E. Lokkevik, S. Lundgren, B. Ostenstad, T. Risberg, I. Mjaaland, T. Aas and P. E. Lonning (2015). [**Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo**](https://pubmed.ncbi.nlm.nih.gov/26004085/) Mol Oncol.  

9.	**Yndestad S**, Eikesdal HP, [**PI3K-Akt-mTOR signallering og Anthracyclinresistens**](https://onkonytt.no/pi3k-akt-mtor-signalering-og-anthracyklinresistens/). Onkonytt. 2014(1).

  
<br>    
      
      
#### Scientific meeting posters  
  
    
1.	**Synnøve Yndestad.** “Digital PD-L1 CPS score: A workflow for Positive cell detection and classification using QuPath.” Bringing AI and Precision Medicine to Patient Care, The Sixth Annual MMIV Conference Bergen (2023). 

2.	PS07-09 Prenatal BRCA1 epimutations is a major cause of triple-negative breast cancer. Per Lonning, Hans Petter Eikesdal, Elisabet Ognedal, Bjornar Gilje, Steinar Lundgren, Egil Blix, Helge Espelid, Jürgen Geisler, Stephanie Geisler, Emiel Janssen, **Synnøve Yndestad**, Laura Minsaas, Beryl Leirvaag, Reidun Lillestol, Stian Knappskog, Oleksii Nikolaienko. SABC (2023). 

3.	**S. Yndestad**, Engebrethsen, C., A. Herencia-Ropero, O. Nikolaienko, O. K. Vintermyr, R. K. Lillestøl, L. Minsaas, B. Leirvaag, G. Iversen, B. Gilje, E. Blix, H. Espelid, S. Lundgren, J. Geisler, L. J. Vassbotn, H. S. Aase, T. Aas, A. Llop-Guevara, V. Serra, P. E. Lønning, S. Knappskog and H. P. Eikesdal. "Abstract P6-10-04: Homologous recombination deficiency across subtypes of primary breast cancer." Cancer Research 83(5_Supplement): P6-10-04-P16-10-04. (2023)  

4.	Eikesdal, H. P., **Yndestad, S.**, Blix, E. S., Lundgren, S., Vagstad, G., Espelid, H., Gilje, B., Janssen, E. A., Geisler, J., Aas, T., Aase, H., Knappskog, S., Lønning, P. E.Neoadjuvant olaparib monotherapy in primary triple negative breast cancer. Annals of Oncology 2019; 30.  

5.	**Synnøve Yndestad**, Eilin Austreid, Ida R. Svanberg, Per E. Lønning, Hans P. Eikesdal. "The Role of Akt in Anthracyclin Resistance in Patients with Locally Advanced Breast Cancer." 4rth CCBIO symposium, Solstrand (2016).  

6.	**Synnøve Yndestad**, Eilin Austreid, Kai Ove Skaftnesmo, Per Eystein Lønning, Hans Petter Eikesdal. "Introduction of Pten Pseudogene in Murine Breast Cancer Upregulates Pten, P53 and Activating Protein 2 Gamma and Delays Tumor Growth.". AACR 106th Annual Meeting 2015; Apr 18–22, 2015; Philadelphia, PA, no. Poster Presentation, Abstract number 3986 (2015).  

7.	**Yndestad Synnøve**, Austreid Eilin, Eikesdal Hans Petter. "The Non-Coding Pten Pseudogene Influences Pi3k Signaling and Inhibits Breast Cancer Progression." AACR 105th Annual Meeting 2014; Apr 5–9, 2014; San Diego, CA, no. Poster presentation, Abstract number 3539 (2014).
8.	Austreid, E. Yndestad, S.  Knappskog, S. Lønning, P.E. Eikesdal, H.P. "The Influence of Doxorubicin on Pten and Pi3k-Akt-Mtor Signaling in Human Breast Cancer." San Antonio Breast Cancer Symposium Poster Presentation  (2013).  

9.	Eikesdal Hans Petter, Austreid Eilin, **Yndestad Synnøve**, Knappskog Stian, Lonning Per Eystein. "Pten Pseudogene Downregulates Pten in Human Breast Cancer." Keystone Poster presentation  (2012).

10. **Yndestad Synnøve**, Roiha Irja Sunde, Torsvik Vigdis, Brandvik Per Johan, Øvreås, Lise.
Microbial community analysis of a hydrocarbon-contaminated arctic soil from Svalbard. 1st Workshop on Microbial ecology and bioremediation in cold climate (MECBIO). Bergen (2002) UiB UNIS

11. **Yndestad Synnøve**, Roiha Irja Sunde, Torsvik Vigdis, Brandvik Per Johan, Øvreås Lise.
Microbial community analysis of a hydrocarbon-contaminated arctic soil from Svalbard. 7th Symposium on Bacterial Genetics and Ecology (BAGECO-7) (2002) UiB UNIS

12. **Yndestad Synnøve**, Roiha Irja Sunde, Øvreås Lise, Brandvik Per Johan.
Oil pollution in the Arctic and its effect on microbial diversity and ecology. Mikrobiologisk vintermøte (2002) UiB UNIS


### PhD thesis 

**The role of PTEN, PI3K-Akt-mTOR signaling and pseudogene PTENP1 in breast cancer**
2018 University of Bergen

[Lint to thesis](https://bora.uib.no/bora-xmlui/handle/1956/17687)


### Master/Cand. Scient thesis  
**Mikrobiell diversitet i oljeforurenset og uberørt tundra på Svalbard**

https://bora.uib.no/bora-xmlui/handle/1956/17687


